Search
Insmed: Revolutionizing Treatment with World's First Approved DPP1 Inhibitor
2025-08-13 /
Read about 0 minute
Author：小编
Brensocatib has exhibited outstanding safety profiles, with side effect rates on par with those observed in the placebo group. The ASPEN study marks a significant milestone for bronchiectasis patients, demonstrating that the drug effectively reduces acute exacerbations and mitigates the decline in lung function, potentially bringing relief to over a million patients worldwide.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
